News

Stephen Ziegler, PhD, JD, explains pain management and prescribing opioid medications in the wake of Ruan v United States.

Elizabeth Volkmann, MD, MS, explains the current treatment options available for SSc-ILD and how to evaluate and manage this patient population.

Elizabeth Volkmann, MD, MS, discusses systemic sclerosis associated interstitial lung disease and how to evaluate subclinical, clinical, and progressive disease for the best outcome.

The new data addressed the lack of studies examining melanoma incidence despite the existence of research examining increases in relative numbers of advanced melanomas during the pandemic.

A cross-sectional analysis of Medicare Part B data spending shows ophthalmologists who received manufacturer funding were less likely to prescribe bevacizumab.

Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and managing director of Opthea Limited, to discuss sozinibercept, a novel recombinant “trap” fusion protein targeting inhibition of VEGF-C and VEGF-D.

New 3-year analysis shows a significant rate of patients were able to avoid relapse or hospitalization while receiving the long-acting injectable.

This research was the result of the first study assessing adaptive smoking cessation treatment within a clinical population using very few criteria for exclusion.

Results from a secondary analysis of PALADIN showed the 0.19-mg implant was associated with mostly stable IOPs in eyes with DME over a 36-month period.

This case report from Brady Pregerson, MD, features a man in his early-30s with chest pain, dizziness, and shortness of breath. Check out the ECG and determine the correct diagnosis!

Performance metrics of NIS4, the ELF test, and FibroMeter VCTE met prespecified criteria for qualification for regulatory approval in stage 1 of the NIMBLE project's circulating biomarker workstream.

Results from the 2-year retrospective cohort study showed patients with DME and extremely high or low eGFR had a greater decline in eGFR.

Jeffrey Sparks, MD, MMSc, explains how to tailor rheumatoid arthritis treatment for an individual patient’s needs and when to consider switching or intensifying treatment.

Yvonne C. Lee, MD, MMSc, explains the pain mechanisms in rheumatic disease and the promising advancements in pain research.

In this segment of her Q&A interview, Dr. Cotton discussed several major topics covered in her upcoming SHSA Conference presentation on pediatric HS.

In this episode, hosts sit down for a discussion around a recent NEJM report assessing the effects of semaglutide use in people with type 1 diabetes, including the implications of the findings and their real-world experiences with GLP-1 use in people with type 1 diabetes.

Susan Goodman, MD, discusses pre and perioperative management of rheumatic disease.

This new Q&A interview with Dr. Cotton featured a discussion on the issues facing pediatric HS patients and other topics covered in her upcoming SHSA Conference presentation.

Patients with CDI treated with oral metronidazole experienced significantly more first-line drug changes compared to those on fidaxomicin, although there were no significant differences observed in the global or clinical cure rate between the two treatments.

On September 7, 2023, Alnylam Pharmaceuticals announced positive topline data from the phase 2 KARDIA-1 trial of zilbesiran in the treatment of hypertension.

Analyses suggest users of calcium channel blockers had 39% higher odds of glaucoma compared with non-users, after controlling for confounders.

This new data had both a consistent long-term safety and tolerability profile with the previous short-term results for the skin disease, and there were no new safety signals recorded.

A program from the American Oncology Network shows promise to introducing cost-efficient biosimilar substitution opportunities to prescribers and payors.

Investigators observed higher rates of clinical and endoscopic remission among patients with UC treated with FMT compared to those on control treatments, further noting comparable rates of adverse reactions between the groups.

An analysis from Taiwan suggest immunogenicity differences are limited between biosimilars approved by the FDA and their reference biologic products.

A treat-and-extend faricimab regimen may improve functional and anatomical outcomes at 1 year in patients with DME recalcitrant to aflibercept treatment.

A case series of 10 patients with newly diagnosed type 1 diabetes provides insight into the beneficial effects of off-label semaglutide use on insulin use, HbA1c, and fasting C-peptide levels among this patient population.

Investigators noted the prevalence of metabolic syndrome was highest among participants with obesity, linking increased BMI to a greater risk of metabolic syndrome and NAFLD severity.